Hawaii Clinical Trials Report — July 2026

Hawaii residents considering a clinical trial should check closing-soon studies now: 8 recruiting trials are projected to close within the next 90 days. Two accept healthy volunteers. Enrollment dates can change, and screening may take time, so people who match a study’s requirements should contact its research site promptly.

At the same time, Hawaii added 5 new trials in July, more than twice the 2 that opened in May. Overall, 203 trials are recruiting across 15 cities and 96 research sites statewide.

Closing opportunities span cancer and neurological conditions

The closing-soon group is concentrated in serious and often highly specific conditions. Breast cancer, colon cancer, lung cancer, ovarian cancer, and other oncology-related diagnoses appear among the studies nearing their projected enrollment deadlines. One trial addresses new-onset generalized myasthenia gravis, while another focuses on cataracts and another on chemotherapy-induced peripheral neuropathy.

• Breast cancer, colon cancer, lung cancer, ovarian cancer, and malignant solid neoplasm — 1 closing-soon trial each
• Cancer and oncology — 1 each
• Cataract — 1
• Chemotherapy-induced peripheral neuropathy — 1
• New-onset generalized myasthenia gravis — 1

Two of the eight closing trials accept healthy volunteers, but the available data do not identify which conditions or interventions those studies involve. Healthy adults should verify eligibility directly rather than assume that a trial listed as recruiting still has open screening appointments.

July brings a major Phase 3 obesity study and new cancer research

Novo Nordisk opened 1 of Hawaii’s most substantial new opportunities this month. The Phase 3 AMAZE 9 study, NCT07720271, plans to enroll 950 participants with excess body weight. It compares once-daily oral zenagamtide tablets with placebo to evaluate safety and weight-loss effectiveness. The study may interest adults who meet its weight-related requirements and are comfortable taking part in a large late-stage drug trial.

Bristol-Myers Squibb also launched a large Phase 3 oncology study in Hawaii. NCT07680790, known as IZABRIGHT-Lung02, plans to enroll 850 people with previously untreated, locally advanced or metastatic EGFR-mutant non-small cell lung cancer. The study compares izalontamab brengitecan combined with osimertinib against osimertinib alone or osimertinib combined with platinum-based chemotherapy. Its design gives eligible patients an opportunity to consider a major sponsor’s comparative treatment study, although individual treatment assignment and eligibility requirements apply.

• NCT07720271 — Novo Nordisk’s Phase 3 study of daily zenagamtide tablets for people with excess body weight; planned enrollment of 950.
• NCT07680790 — Bristol-Myers Squibb’s Phase 3 IZABRIGHT-Lung02 study for previously untreated EGFR-mutant non-small cell lung cancer; planned enrollment of 850.
• NCT07723963 — Jazz Pharmaceuticals’ Phase 2/Phase 3 study evaluating the safety and efficacy of JZP926 capsules for juvenile myoclonic epilepsy; planned enrollment of 260.
• NCT07705945 — Brooke Army Medical Center’s study comparing in-person and remote physical therapy for musculoskeletal pain within the Military Health System; planned enrollment of 210.

Jazz Pharmaceuticals’ NCT07723963 is notable because it bridges Phase 2 and Phase 3 research in juvenile myoclonic epilepsy. Families and adults affected by this form of epilepsy should review the study’s age, seizure-history, medication, and other requirements with the research team. Brooke Army Medical Center’s NCT07705945 is different from the month’s drug-focused studies: it examines whether telehealth can expand access to physical therapy for musculoskeletal pain in the Military Health System.

Five new studies reflect a mostly industry-led pipeline

Hawaii’s July additions include studies involving COVID-19 vaccines, juvenile myoclonic epilepsy, musculoskeletal pain, non-small cell lung cancer, obesity, and overweight. Because one trial can list more than one condition, the condition count includes both obesity and overweight among the new research areas.

• COVID-19 vaccines — 1 new trial
• Juvenile myoclonic epilepsy — 1
• Musculoskeletal pain — 1
• Non-small cell lung cancer — 1
• Obesity and overweight — 1 each

Drug studies account for 3 of the five new trials. One is biological and one is classified as another type. Four new trials are industry-sponsored, while one is federally sponsored. New sponsors include BioNTech SE, Bristol-Myers Squibb, Jazz Pharmaceuticals, Novo Nordisk A/S, and Brooke Army Medical Center.

The increase from two new trials in May to five in July suggests a more active opening month, especially for late-stage drug research. The recent six-month pattern has varied: Hawaii recorded three new trials in February, four in March, three in April, two in May, two in June, and five in July. The available trend also lists two for August, indicating that the state’s trial pipeline may continue to shift quickly.

Honolulu dominates July openings

New recruitment is highly concentrated geographically. Honolulu accounts for 4 of the five new trials, while Tripler AMC accounts for 1. These locations are part of Hawaii’s broader network of 96 research sites across 15 cities.

• Honolulu — 4 new trials
• Tripler AMC — 1 new trial

The July pattern points to a metropolitan and military-medical concentration rather than an even statewide spread. People living outside Honolulu or Tripler AMC may need to ask whether a study offers another Hawaii site, remote prescreening, telehealth visits, or travel support. The physical therapy study may be especially relevant to people connected with the Military Health System, but participation depends on the protocol’s specific eligibility rules.

Healthy volunteers and families have limited new options

Only 1 of 5 new trials accepts healthy volunteers, while 27 healthy-volunteer studies are recruiting statewide in total. That makes the new-trial opportunity for people without a diagnosed condition relatively narrow this month. Healthy adults should search the full statewide group rather than focus only on July openings, while also checking whether a study requires a particular age, vaccination history, location, or other characteristic.

One new trial includes children, and 3 new trials include older adults. No new trials are designated female-only or male-only. These figures suggest that most July opportunities are aimed at broader adult populations, but parents of eligible children and older adults should still review the individual protocols because age ranges differ substantially between studies.

Patients with non-small cell lung cancer, people with excess body weight, and those living with juvenile myoclonic epilepsy may have the clearest reasons to act now, particularly if they can reach a Honolulu-area or Tripler AMC site. People affected by the closing cancer, cataract, neuropathy, or myasthenia gravis studies should begin with those time-sensitive listings before exploring newer openings.

As Hawaii moves through the rest of 2026, residents can expect recruitment to remain centered around Honolulu and Tripler AMC while late-stage industry studies add opportunities in obesity, oncology, epilepsy, vaccines, and pain care. Checking listings early and confirming site availability directly will give eligible participants the best chance to enter before enrollment windows change.